Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 302-309

  Zhang, Haoming ^a   Lau, Wei C ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CLOPIDOGREL; CYSTEINE; DITHIOTHREITOL; DRUG METABOLITE; GLUTATHIONE; THIOLACTONE;

ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HUMANS; MICROSOMES, LIVER; OXIDATION-REDUCTION; SULFHYDRYL COMPOUNDS; TICLOPIDINE;

EID: 84863907523     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079061     Document Type: Article

References (30)

1. Algaier I, Jakubowski JA, Asai F, and von Kügelgen I (2008) Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 6:1908-1914.
2. Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, and Taubert D (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110-116.
3. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-317.
4. Dansette PM, Libraire J, Bertho G, and Mansuy D (2009) Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem Res Toxicol 22:369-373.
5. Dansette PM, Rosi J, Bertho G, and Mansuy D (2011) Paraoxonase-1 and clopidogrel efficacy. Nat Med 17:1040-1041.
6. Dansette PM, Rosi J, Bertho G, and Mansuy D (2012) Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 25:348-356.
7. Ding Z, Kim S, Dorsam RT, Jin J, and Kunapuli SP (2003) Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101:3908-3914.
8. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, and Gaussem P (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989-995.
9. Fruton JS (1934) Oxidation-reduction potentials of ascorbic acid. J Biol Chem 105:79-85.
10. Hagihara K, Kazui M, Kurihara A, Kubota K, and Ikeda T (2011) Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel. Drug Metab Dispos 39:208-214.
11. Houk J, Singh R, and Whitesides GM (1987) Measurement of thiol-disulfide inter-change reactions and thiol pKa values. Methods Enzymol 143:129-140.
12. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247.
13. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, Cayla G, Beygui F, and Montalescot G (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 56:134-143.
14. Jocelyn PC (1967) The standard redox potential of cysteine-cystine from the thioldisulphide exchange reaction with glutathione and lipoic acid. Eur J Biochem 2:327-331.
15. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, and Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99.
16. Mason PJ, Jacobs AK, and Freedman JE (2005) Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46:986-993.
17. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362.
18. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830.
19. Meister A and Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760.
20. Noszál B, Visky D, and Kraszni M (2000) Population, acid-base, and redox properties of N-acetylcysteine conformers. J Med Chem 43:2176-2182.
21. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, and Picard C (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288-1295.
22. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, and Maffrand JP (1992) Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 44:527-532.
23. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Hervé C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, et al. (2006) The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 103:11069-11074.
24. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857.
25. Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, and Dubar M (2011) Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 90:287-295.
26. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, and Kim HS (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174:1715-1722.
27. Takahashi M, Pang H, Kawabata K, Farid NA, and Kurihara A (2008) Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 48:1219-1224.
28. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, and Schömig E (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486-501.
29. Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon MC, Hurbin F, et al. (2011) An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105:696-705.
30. Zhang H, Amunugama H, Ney S, Cooper N, and Hollenberg PF (2011) Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme. Mol Pharmacol 80:839-847.